Ibrutinib for treating Waldenstrom’s macroglobulinaemia

2.1 Ibrutinib (Imbruvica, Janssen) has a marketing authorisation for treating 'adult patients with Waldenstrom's macroglobulinaemia who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy'.

2.2 The dosage schedule is available in the summary of product characteristics for ibrutinib.

2.3 The list price for ibrutinib is £1,430.80 for a 28‑tablet pack of 140 mg tablets (excluding VAT; BNF online accessed December 2021).

2.4 The company has a commercial arrangement. This makes ibrutinib available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.